Infants born to mothers who were immunized with an investigational vaccine against respiratory syncytial virus — or RSV — received antibodies across the placenta, with no “evident safety concerns,” results from a phase 2b trial showed.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045